Target audience
This module is aimed at medical professionals interested in the field of immuno-oncology.
Learning objectives
By the end of this module you will be able to:
-
Describe why melanoma is a model tumour for immunotherapy
-
Understand the key developments in immunotherapy treatment for melanoma
-
Understand the use of checkpoint inhibitors in the adjuvant setting
IT Requirements
This module requires the learner to have a good, stable internet connection and can run on Internet Explorer 7 and above, Mozilla Firefox, Google Chrome and Opera on either Windows or MacOS. Flash Add-on is also required to run this module.
If you are viewing this module on an iPad (through a browser), please download the free Articulate Mobile Player beforehand. Other tablet devices may not be compatible - please check for Flash compatibility.
If you are experiencing technical difficulties, please contact education@ecancer.org and we will get back to you as soon as possible.
Disclosure policy
ecancer and everyone involved in the development of this module has no actual or potential conflict of interest whatsoever which impinges on the making, peer reviewing and dissemination of this e-learning module which was made possible through an unrestricted educational grant from the Bristol-Myers Squibb Foundation and AbbVie Inc.
Both the BMS Foundation and AbbVie Inc. have had no input in the creation of the e-learning materials including the process of selecting speakers.
For more information, please email education@ecancer.org
Support
Production of this module was funded by an unrestricted grant from The Bristol-Myers Squibb Foundation and AbbVie Inc.
